Uterine metastasis of lung adenocarcinoma under molecular target therapy with epidermal growth factor receptor tyrosine kinase inhibitors: A case report and review of the literature. Issue 2 (2nd November 2017)

• Record Type: Journal Article
• Authors: Shibata, Mayu; Shizu, Masato; Watanabe, Kazuko; Takeda, Akihiro
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 44:Issue 2(2018)
• Page Start: 352
• Page End: 358
• Publication Date: 2017-11-02
• Subjects: epidermal growth factor receptor gene mutation -- lung adenocarcinoma -- molecular target therapy -- tyrosine kinase inhibitor -- uterine metastasis; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13493
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: A 63‐year‐old woman presented with abnormal vaginal bleeding. Her disease history was significant, and included advanced lung adenocarcinoma with a deletion mutation in exon 19 of the epidermal growth factor receptor ( EGFR ) gene, which was managed by concurrent chemoradiotherapy, followed by molecular targeted therapy with tyrosine kinase inhibitors (TKIs) for a two‐year period. Contrast‐enhanced computed tomography showed the enlargement of a previously suspicious myoma node, with peripheral enhancement. Hemorrhagic necrosis was also observed on magnetic resonance imaging. Transabdominal hysterectomy and bilateral salpingo‐oophorectomy showed solitary intramyometrial metastatic lung adenocarcinoma with a second‐site T790M gatekeeper mutation in exon 20 of the EGFR gene. In conclusion, uterine metastasis from lung adenocarcinoma can present a diagnostic challenge. The possibility of lung cancer metastasis should be considered when a uterine mass increases in size during treatment. Molecular analysis of the EGFR gene to detect mutations could provide useful information for planning the treatment strategy.